Combinatorial treatment against metastatic colorectal cancer

SUMMARY

Colorectal cancer is the third most diagnosed cancer and fourth most common cause of death worldwide, metastasis being the cause of about 90% of deaths. The team has previously identified a key driver and novel biomarker of metastasis formation. Moreover, new inhibitory compounds able to inhibit this metastasis driver were identified through high throughput screening with former SPARK support. During the current funding period, the team will evaluate these inhibitors for their ability to restrict tumor progression and metastasis formation with adequate \textit{in vivo} tolerability. Furthermore, the molecular action of the colorectal cancer biomarker will be explored further.

PRINCIPAL INVESTIGATORS:
Prof. Dr. Ulrike Stein,
Prof. Dr. Wolfgang Walther,
Dr. Dennis Kobelt, Paul Curtis Schöpe
MDC & Charité

PROJECT GOALS

• ADMET characterization and mode of action assessment of identified hit compounds
• MedChem analysis, design and synthesis to obtain lead compounds
• \textit{In vivo} testing of lead compounds for antitumoral and antimetastatic activity

LONG-TERM GOALS

• Clinical trial phase I
• Licensing to Pharma